CalciMedica (CALC) CEO Leheny Rachel Receives 360,000-Share Award

What Happened

• Leheny A. Rachel, CEO of CalciMedica, was granted 360,000 shares (reported as a derivative award) on 2026-09-24. The reported acquisition price is $0.00, so no cash was paid at grant. This was an equity award (Form 4 code A), not a purchase or sale.

Key Details

• Transaction date: 2026-09-24; Form 4 filed: 2026-09-28.
• Grant size and price: 360,000 shares awarded at $0.00.
• Vesting: Per the filing footnote, beginning September 24, 2026, 1/48th of the shares will vest in equal monthly installments over four years.
• Shares owned after transaction: Not specified in the provided data.
• Filing timeliness: The Form 4 was filed four days after the transaction date; insiders normally have two business days to file, so this appears later than the typical deadline.

Context

• This is an award of derivative securities (commonly structured as restricted stock units or similar) that are subject to vesting and are not immediately free to sell. No immediate sale or cashless exercise was reported. As with most grants, this is a compensation/retention action and should be viewed differently than an open-market purchase or sale.